fetching data ...

AB0297 (2026)
PERSONALIZED OUTREACH AND EQUITABLE TREATMENT IN RHEUMATOLOGY
Keywords: Patient Reported Outcome Measures, Health services research, Diversity, Equity, And Inclusion (DEI), Qualitative research, Quality of care
A. Yu1, N. Saleh2, D. Choudhary1, G. Montesano2, M. Kestler3, A. Palepu2,4, B. Ohata1
1University of British Columbia, Rheumatology, Vancouver, Canada
2University of British Columbia, Medicine, Vancouver, Canada
3University of British Columbia, Infectious Diseases, Vancouver, Canada
4Centre for Health Evaluation & Outcome Sciences (CHÉOS), Vancouver, Canada

Background: Individuals living with rheumatic disease who are marginalized by extreme poverty and housing instability suffer dramatically worse outcomes [1,2]. Those living in Vancouver’s Downtown Eastside experience high rates of substance use disorder, mental illness, and early mortality.[3] Since 2019, the Mary Pack Arthritis Program has operated a twice-monthly Rheumatology Clinic (“the Clinic”) in partnership with the Pender Community Health Centre, an inner-city primary care unit in Vancouver, Canada. Although this Clinic has lowered barriers to accessing care, challenges remain in adherence to follow-up appointments, monitoring labwork, and sustaining DMARD therapy.


Objectives: Our study aimed to first review the Clinic’s service provision and subsequently design and pilot an intervention to improve patient engagement in the care of their rheumatic disease.


Methods: We utilized a mixed-methods approach beginning with a retrospective chart review of all patients seen at the Clinic from January 2022 until June 2025. We concurrently conducted interviews with Clinic rheumatologists, inner-city primary care physicians, and patient representatives to understand specific barriers. Based on these findings, we designed a prospective trial for patients with inflammatory arthritis referred from local inner city community health centers. The intervention included a $20 honorarium for each follow-up visit they attended with completed bloodwork as well as a Rheumatology-specific outreach service that provided personalized education, advice, and appointment reminders. The primary outcome was the rate of attendance to follow-up visits in the study group compared to historical controls. The study was approved by the UBC REB (H24-03984).


Results: Between January 2022 and June 2025, the Clinic treated 167 unique patients (Table 1). The baseline rate of attendance to follow-up visits was 52.6% overall, and 42.4% among patients with a confirmed systemic autoimmune rheumatic disease. The patient population had high rates of comorbidity: 77% had substance use disorders, while 59% had mental health disorders. Housing instability was nearly universal; 12% of patients were unhoused, while 78% lived in modular, transitional, or single-room occupancy (SRO) housing. At a planned interim analysis of the prospective study (n=9), the rate of adherence to follow-up visits was significantly improved compared to historical controls (90.5% vs 42.4%, p < 0.001). For participants who were previously patients at the Clinic, follow-up rates improved compared to personal priors (87.5% vs 43.5%, p < 0.001). No concerning safety signals were identified.


Conclusions: Standard models of care are often insufficient for marginalized populations. An intervention combining modest financial incentives and specialized outreach support may improve adherence to follow-up in this cohort.

Characteristic n (%) or Mean (SD)
Total Patients 167
Sex
Male 85 (50.9%)
Female 82 (49.1%)
Age (years )
Mean (SD) 53.3 (12.5)
Housing Status
Low barrier supportive housing 75 (44.9%)
Single-room occupancy hotels 40 (24.0%)
Unhoused 22 (13.2%)
Modular or transitional housing 15 (9.0%)
Market housing 15 (9.0%)
Reason for Referral
Possible systemic autoimmune rheumatic disease 108 (64.7%)
Mechanical/soft tissue pain 31 (18.6%)
Crystalline arthritis 12 (7.2%)
Other 16 (9.6%)
Comorbidities
Substance use disorder* 129 (77.2%)
Mental health disorder** 99 (59.3%)
Appointment Adherence
All Patients
Total follow-ups made 435
Total follow-ups attended 229
Adherence Rate 52.60%
Patients with Confirmed SARD***
SARD follow-ups made 269
SARD follow-ups attended 114
Adherence Rate 42.40%

*Defined as opioid use, stimulant use, or alcohol use disorder.

**Defined as depression, anxiety, bipolar disorder, schizophrenia and other chronic psychosis, or PTSD.

***SARD: Systemic Autoimmune Rheumatic Disease.


REFERENCES: [1] Rai B. Clin Rheumatol 2022; 41(6):1653-1657.

[2] Seta R. Clin Rheumatol 2020; 40(1):413-420.

[3] Vila-Rodriquez F. Am J Psychiatry 2013; 170(12):1413-1422.


Acknowledgments: NIL.


Disclosure of Interests: None declared.


DOI: annrheumdis-2026-eular.B.2227
Keywords: Patient Reported Outcome Measures, Health services research, Diversity, Equity, And Inclusion (DEI), Qualitative research, Quality of care
Citation: , volume 85, supplement 1, year 2026, page s1566
Session: Clinical research - Across diseases (Publication Only)